ArticleCell metabolism2019
A Long-Acting PYY
Open access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Long-acting PYYObesity (Silver Spring, Md.) · 2025Trial
- Gut Microbiome in Obesity: A Narrative Review of Mechanisms, Interventions, and Future Directions.Probiotics and antimicrobial proteins · 2026Review
- GIPR signaling modulates PYY-induced hypophagia and malaise in rodents.Molecular metabolism · 2026Article
- Molecular Design of Unimolecular Tetra-Receptor Agonists.Journal of the American Chemical Society · 2025Article
- Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacology research & perspectives · 2024Review
- Article
- The antiemetic actions of GIP receptor agonism.American journal of physiology. Endocrinology and metabolism · 2024Review
- Effects of NPY-2 Receptor Antagonists, Semaglutide, PYYNutrients · 2024Article
- Article
- PYYNeuropharmacology · 2023Article
- 360-Degree Perspectives on Obesity.Medicina (Kaunas, Lithuania) · 2023Review
- Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023Review
- G protein-coupled receptors and obesity.Frontiers in endocrinology · 2023Review
- GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior.Diabetes · 2022Article
- Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.Endocrine reviews · 2022Review
- Targeting the Enteroendocrine System for Treatment of Obesity.Handbook of experimental pharmacology · 2022Article
- The effect of fatty diacid acylation of human PYYScientific reports · 2021Article
- Rational Development of Stable PYYPharmaceutical research · 2021Article
- From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators.Microbiome · 2021Review
- Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.Scientific reports · 2021Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 4 institutions in 1 country.
Shamina M RangwalaDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA. Electronic address: srangwal@its.jnj.com.
Katharine D'AquinoDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Yue-Mei ZhangDiscovery Sciences, Janssen Research and Development, Spring House, PA, USA.
Lindsay BaderOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Wilson EdwardsJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Songmao ZhengJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Annette EckardtDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Ann LacombeJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Rebecca PickDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Veronica MorenoDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Lijuan KangDiscovery Sciences, Janssen Research and Development, Spring House, PA, USA.
Wenying JianDiscovery Sciences, Janssen Research and Development, Spring House, PA, USA.
Eric ArnoultDiscovery Sciences, Janssen Research and Development, Spring House, PA, USA.
Martin CaseJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Celia JenkinsonDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Ellen ChiJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Ronald V SwansonJanssen Biotherapeutics, Janssen Research and Development, La Jolla, CA, USA.
Paul KievitOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Kevin GroveOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Mark MacielagDiscovery Sciences, Janssen Research and Development, Spring House, PA, USA.
Mark D ErionDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA.
Ranabir SinhaRoyExperimental and Translational Medicine, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Raritan, NJ, USA.
James N LeonardDiscovery Biology, Cardiovascular and Metabolic Therapeutic Areas, Janssen Research and Development, Spring House, PA, USA. Electronic address: jleonar7@its.jnj.com.
Janssen (United States) · USSpringhouse · USOregon Health & Science University · USOregon National Primate Research Center · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MNIH HHS P51 OD011092
Abstract
The gut hormone PYY
Indexed as
VomitingAnimalsAnorexiaCHO CellsCricetulusGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHEK293 CellsHumansLiraglutideMacaca mulattaMiceMice, Inbred C57BLObesityPeptide YYGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLiraglutidePeptide YYbody weightemesisfood intakegastric bypass surgeryGLP-1gut peptide hormoneobesityPYY(3-36)tolerability
Identifiers
What OpenQuestion holds
Texttitle and abstract
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.